BOULDER, Colo., May 9, 2019 /PRNewswire/ -- Array BioPharma Inc.
(Nasdaq: ARRY) today announced that its Chief Executive Officer,
Ron Squarer, will speak at the Bank
of America Merrill Lynch 2019 Health Care Conference in
Las Vegas. The public is welcome
to participate in the conference through a webcast on the Array
BioPharma website.
Event:
|
Bank of America
Merrill Lynch 2019 Health Care Conference
|
Presenter:
|
Ron Squarer, Chief
Executive Officer, Array BioPharma
|
Date:
|
Thursday, May 16,
2019
|
Time:
|
10:00 a.m. Pacific
Time / 1:00 p.m. Eastern Time
|
Webcast:
|
http://www.veracast.com/webcasts/baml/healthcare2019/id83306305205.cfm
|
About Array BioPharma
Array BioPharma Inc. is a fully integrated biopharmaceutical
company focused on the discovery, development and commercialization
of transformative and well-tolerated targeted small molecule drugs
to treat patients afflicted with cancer and other high-burden
diseases. Array markets BRAFTOVI® (encorafenib) capsules
in combination with MEKTOVI® (binimetinib) tablets for
the treatment of patients with unresectable or metastatic melanoma
with a BRAFV600E or BRAFV600K
mutation in the United States and
with partners in other major worldwide markets. Array's lead
clinical programs, encorafenib and binimetinib, are being
investigated in over 30 clinical trials across a number of solid
tumor indications, including a Phase 3 trial in BRAF-mutant
metastatic colorectal cancer. Array's pipeline includes several
additional programs being advanced by Array or current
license-holders, including the following programs currently in
registration trials: selumetinib (partnered with AstraZeneca),
LOXO-292 (partnered with Eli Lilly), ipatasertib (partnered with
Genentech), tucatinib (partnered with Seattle Genetics) and
ARRY-797. Vitrakvi® (larotrectinib, partnered with Bayer
AG) is approved in the United
States and Ganovo® (danoprevir, partnered with
Roche) is approved in China. For
more information on Array, please visit www.arraybiopharma.com or
follow @arraybiopharma on Twitter and LinkedIn.
BRAFTOVI® and MEKTOVI® are registered
trademarks of Array BioPharma Inc. in the
United States and various other countries.
Erbitux® is a registered trademark of Eli Lilly and
Company. Vitrakvi® is a registered trademark of Bayer
AG. All trademarks are properties of their respective owners.
CONTACT:
Andrea N. Flynn, Ph.D.
Senior Director, Investor Relations & Corporate
Communications
(303) 381-6600
ir@arraybiopharma.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/array-biopharma-to-present-at-the-bank-of-america-merrill-lynch-2019-healthcare-conference-300847448.html
SOURCE Array BioPharma Inc.